• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

POZEN To Present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference

Posted on: Monday, 30 April 2007, 15:04 CDT

POZEN Inc. (NASDAQ:POZN) announced today that William L. Hodges, the company's chief financial officer, will present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference on Tuesday, May 8, 2007 at 12:30 p.m. (ET) at the Grand Hyatt in New York City. Mr. Hodges' presentation will be webcast and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience

. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima™ combining sumatriptan, formulated with RT Technology™, and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Source: Business Wire

More News in this Category